Creative Medical Technology (NASDAQ:CELZ – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02), FiscalAI reports.
Creative Medical Technology Stock Up 23.5%
CELZ traded up $0.27 during trading on Friday, reaching $1.42. The stock had a trading volume of 63,848,181 shares, compared to its average volume of 15,995,997. The firm has a market capitalization of $6.73 million, a price-to-earnings ratio of -0.66 and a beta of 1.94. Creative Medical Technology has a 1-year low of $0.62 and a 1-year high of $6.25. The stock has a 50 day moving average of $1.39 and a two-hundred day moving average of $1.83.
Creative Medical Technology News Roundup
Here are the key news stories impacting Creative Medical Technology this week:
- Positive Sentiment: The USPTO issued a Notice of Allowance for a patent covering exosomes from stem-cell-programmed myeloid cells. The technology is designed to promote antigen-specific immune tolerance and reduce the autoimmune destruction of insulin-producing pancreatic cells in Type 1 diabetes. The patent would strengthen protection around the MyeloCelz™ platform and complement CELZ’s CELZ-101 and CELZ-201 programs. Creative Medical patent announcement
- Positive Sentiment: Creative Medical said its intellectual-property estate now includes approximately 60 issued patents and pending applications, with plans to advance clinical programs, generate additional data and explore licensing or strategic partnerships. This gives traders a larger commercial and partnership narrative around the company’s diabetes franchise. Business Insider patent coverage
- Neutral Sentiment: Trading was halted several times under Limit Up-Limit Down rules, indicating extreme volatility. Analysts attributed the rally partly to retail momentum, CELZ’s small public float and renewed interest in earlier pipeline and financing updates rather than to new clinical results. Quiver Quantitative CELZ trading analysis
- Negative Sentiment: The patent remains investigational: a Notice of Allowance does not guarantee final issuance or meaningful commercial protection, and no MyeloCelz product has FDA approval. Clinical, regulatory and manufacturing risks remain significant.
- Neutral Sentiment: Investors are also awaiting Creative Medical’s quarterly earnings report, expected Friday. The release could provide updates on cash resources, losses and progress in the CELZ-101 and CELZ-201 programs. Expected quarterly earnings report
Analysts Set New Price Targets
View Our Latest Research Report on Creative Medical Technology
Institutional Trading of Creative Medical Technology
An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent SEC filing. 1.42% of the stock is currently owned by institutional investors.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.
The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.
Featured Stories
- Five stocks we like better than Creative Medical Technology
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
